GHTF (Global Harmonisation Task Force) & MRAs (Mutual Recognition Agreements) - the highs and lows of global regulatory efforts
This article was originally published in Clinica
Executive Summary
Much has been achieved towards encouraging bilateral and even global acceptance of different regulatory approaches as well as towards converging standards requirements in key areas. Indeed, regulatory compliance is becoming easier for international manufacturers and future business is looking good for certification bodies offering one-stop testing. But 2003 was not an easy year for the regulators, as Amanda Maxwell reports
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.